尼可霉素生物合成基因簇的改造及其异源表达

摘要:【目的】异源表达尼可霉素生物合成基因簇,为尼可霉素核苷和肽基缩合机制研究以及尼可霉素与其它核苷类抗生素的组合生物合成奠定基础。【方法】以含有尼可霉素生物合成基因簇的pNIK 为出发质粒,通过PCR-targeting 的方法,将基因簇中sanG和sanF的启动子替换为组成型hrdB启动子,构建重组质粒pNIKm。通过接合转移的方法分别将pNIK和pNIKm导入天蓝色链霉菌M1146中,获得异源表达菌株M1146-NIK和M1146-NIKm,并通过RT-PCR检测基因簇的表达情况。最后通过抗菌活性实验和产物的分离 鉴定,比较M1146-NIK和M1146-NIKm的抗菌活性和尼可霉素的产生情况。【结果】pNIK和pNIKm在异源宿主天蓝色链霉菌M1146成功表达; M1146-NIK和M1146-NIKm均有明显的抗菌活性; M1146-NIK和M1146-NIKm均能产生少量的尼可霉素X、Z和假尼可霉素Z;M1146-NIK大量积累尿苷,而M1146-NIKm大量积累尿苷、核糖基-4-甲酰-4-咪唑-2-酮和吡啶同型苏氨酸。【结论】尼可霉素生物合成基因簇成功异源表达,并分离鉴定了尼可霉素产物及其生物合成中间体。本研究将为尼可霉素核苷和肽基缩合的酶学机制研 究以及尼可霉素与其它核苷类抗生素组合合成新型杂合抗生素提供理论依据和指导。     

圈卷产色链霉菌san7324和san7324L基因阻断对形态分化和尼可霉素产生的影响

【目的】圈卷产色链霉菌全局性调控基因wblA阻断突变后,尼可霉素不再产生。RNA-seq和转录分析表明san7324基因在野生型菌株中可以正常转录,而在wblA阻断突变株(ΔwblA)中不能转录,为此本文旨在揭示san7324与尼可霉素产生的关系。【方法】利用同源双交换策略对san7324进行基因阻断,而后通过基因遗传回补及对尼可霉素生物合成相关基因的转录分析等方法研究san7324的功能。【结果】在相同培养条件下,阻断突变株Δsan7324与野生型菌株相比失去了合成尼可霉素的能力。我们通过同源比对发现圈卷产色链霉菌中还存在一个与san7324同源的基因san7324L,该基因的阻断导致尼可霉素产量降低。当san7324和san7324L两个基因同时被阻断后,得到的突变株Δsan7324-san7324L生长稀疏而且不能正常发育分化形成灰色表型的孢子或孢子链,只能形成白色表型的气生菌丝,同时也丧失了合成尼可霉素的能力。当这两个基因(san7324-san7324L)回补双突变株后,则恢复了野生型的表型(能形成孢子链并恢复尼可霉素的产生)。进一步的研究初步表明san7324和san7324L的阻断主要影响了尼可霉素生物合成基因簇中途径特异性调控基因sanG的转录水平,从而影响圈卷产色链霉菌的发育分化和尼可霉素的产生。【结论】该结果为链霉菌形态分化与生理代谢关系的研究提供了更多的证据,同时为多效调控基因wblA作用机制的阐明奠定了基础。     

圈卷产色链霉菌尼可霉素生物合成基因sanA的克隆、结构和功能

圈卷产色链霉菌是尼可霉素产生菌,经紫外线诱变后,以赤星灰霉为指示菌筛选到遗传稳定的尼可霉素生物合成阻断突变株,选择其中的NBB19为受体,以质粒pIJ702为克隆载体,从野生型圈卷产色链霉菌的DNA文库中克隆到了6kb的DNA片段,能互补NBB19使之恢复尼可霉素的产生能力.对6kbDNA片段中的部分片段进行了序列分析,结果表明2710bpDNA片段包含一个1365bp的完整开放阅读框架,编码一个由454个氨基酸残基组成的蛋白质,该基因命名为sanA.蛋白序列数据库比较结果表明,sanA编码的蛋白质氨基酸序列与Pyrococcus horikoshii的甲基转移酶有较高的同源性,353个氨基酸残基中有25%的一致性.用基因破坏策略研究了sanA的功能,野生型菌株sanA基因被破坏后导致失去合成尼可霉素的能力,表明sanA是尼可霉素生物合成中的一个新的重要基因.     

真菌次级代谢产物rasfonin促进舒尼替尼(Sunitinib)诱导的肾癌细胞自噬和凋亡

【目的】明确真菌次级代谢产物rasfonin影响舒尼替尼(Sunitinib,ST)诱导的肾癌细胞自噬和凋亡作用机理。【方法】应用MTS(Methanethiosulfonate assay)和克隆形成实验检测rasfonin和舒尼替尼对肾癌细胞ACHN活性和增殖的影响,通过透射电子显微镜、荧光显微镜、蛋白免疫印迹、免疫荧光方法检测rasfonin和舒尼替尼处理的ACHN细胞自噬、凋亡情况和相关信号通路的变化。【结果】Rasfonin和舒尼替尼能够抑制肾癌细胞ACHN活性和细胞增殖;免疫印迹结果表明,两者均可以引起caspase依赖的凋亡。在rasfonin存在的情况下,不仅舒尼替尼所引起的凋亡和细胞活性丢失明显增加,而且其诱导的自噬流显著提高。无论是rasfonin还是舒尼替尼均明显地抑制哺乳雷帕霉素靶蛋白m TOR(Mammal target of rapamycin)磷酸化,而两者均能促进细胞外调节蛋白激酶(Extracellular regulated protein kinases,ERK)活性增加。【结论】rasfonin促进了舒尼替尼诱导的细胞自噬和凋亡,提高了舒尼替尼抑制肾癌细胞增殖的活性。     

黏细菌资源与埃博霉素研发

由黏细菌作为天然活性物质的重要资源已经逐步受到重视,掌握黏细菌的特点可有效解决黏细菌资源开发中遇到的一些问题.抗肿瘤活性物质埃博霉素作为黏细菌次级代谢产物的杰出代表已经被成功开发成药物,同时埃博霉素家族的其他几种化合物也正在进行临床研究,埃博霉素将成为人类抗癌药物领域的重要力量.埃博霉素的发酵生产也会得到越来越广泛的研究.     

圈卷产色链霉菌尼可霉素生物合成基因——sanH和sanI的研究

通过反向遗传学方法克隆到圈卷产色链霉菌尼可霉素生物合成基因簇中约7.0kb的DNA片段。该片段除含有尼可霉素生物合成基因sanF外,对sanF上游约22kb的BglⅡDNA片段进行序列测定及分析表明,还含有两个完整的开放阅读框(ORF)。ORF1由1233个核苷酸组成,ORF2由195个核苷酸组成,它们分别编码由410个氨基酸残基和64个氨基酸残基组成的蛋白质,依次命名为sanH和sanI。蛋白序列数据库比较结果表明,SanH和SanI与浅灰链霉菌(\%Streptomyces griseolus)\%中共转录的细胞色素P450(cytochrome P450)和铁氧还蛋白(ferredoxin)有较高的同源性,一致性分别为46%和56%,相似性分别为62%和70%。基因功能研究表明,sanH基因的破坏虽不影响圈卷产色链霉菌产生的尼可霉素的生物活性,但该基因可能参与了尼可霉素羟基化反应的生物合成。     

硫霉素环化酶基因在变铅青链霉菌TK24中的表达及基因定位

将含有硫霉素环化酶基因的重组质粒p6BCl2转化变铅青链霉菌(Streptomyceslividans)TK24,含有p6BCl2的转化子细胞抽提液分别与琉霉素生物合成阻断变株Y,发酵液以及纯化的Y。中间产物经过体外共培养可产生活性物质．化学分析表明与Y,发酵液混合后产生的是硫霉素,与纯化的Y。中间产物混合产生的是一种不稳定的活性物质。说明硫霉素环化酶基因在S.lividans TK24中得到了表达,其产物以Y。中间产物为底物并弥补了Y,中的缺陷。对p6Bcl2中4．5kb外源片段进行了限制酶酶切分析,建立了酶切图谱．利用含硫霉素环化酶基因的S．Lividans TK24转化子体外转化Y,的应用体系,将硫霉素环化酶基因定位在0．9kb Hinc I—Pst I片段上,并证明了硫霉紊环化酶的活性与IPNS同源片段无关。以上实验为进一步研究琉霉素环化酶基因的结构打下了基础。     

达托霉素生物合成研究进展

达托霉素是由玫瑰孢链霉菌(Streptomyces roseosporus)生产的一种环脂肽类抗生素, 具有强大的抗革兰氏阳性致病细菌的作用, 是继“抗生素最后一道防线”万古霉素后的新型抗生素。本文主要对达托霉素的结构、作用机制、合成基因簇及合成机制等当前的研究成果进行综述, 并且总结了利用组合生物学对达托霉素进行结构改造的策略, 以此来研究结构与活性之间的关系, 并寻找更广谱高效的抗生素。最后, 本文总结了提高达托霉素产量的策略, 为工业上降低达托霉素生产成本提供理论参考。     

盐霉素类似物的分离及抑制吲哚胺2,3-双加氧酶活性研究

为研究盐霉素发酵粗产物中的新型盐霉素类活性化合物。实验通过制备色谱从盐霉素发酵粗产物中分离得到两个盐霉素类似物,并利用波谱手段表征了这两个化合物的结构,化合物A为40-甲基盐霉素,化合物B为35-甲基盐霉素,均为新化合物。生物活性研究表明,化合物B具有一定的吲哚胺2,3-双加氧酶(IDO)抑制活性。     

抗癌抗生素格尔德霉素衍生物17AAG的研究进展

格尔德霉素是一种苯醌安莎霉素类抗生素,有极强的抗肿瘤活性,其衍生物 17AAG (17- 丙烯胺 -17- 去甲氧基格尔德霉素 ) 是 格尔德霉素的 17 位甲氧基被烯丙胺基取代所得,与格尔德霉素相比,其毒性更低,抗癌活性更高。综述 17AAG 的作用机制、治疗应用、 药代动力学、毒性等研究进展。     

Cloning, Sequencing, and Function of sanF: A Gene Involved in Nikkomycin Biosynthesis of Streptomyces ansochromogenes

A 111-bp DNA fragment related to nikkomycin biosynthesis of Streptomyces ansochromogenes 7100 was obtained with the method of reverse genetics. Then, a 2.2-kb DNA fragment was cloned from the DNA library of S. ansochromogenes 7100 by using the 111-bp fragment as a probe. Sequence analysis showed that the fragment contains one complete open reading frame (ORF) that encodes a 219-amino acid (aa) protein, and this gene was designated sanF (GenBank Accession No. AF223971). The function of the sanF gene was studied by a strategy of gene disruption, and the resulting sanF mutants lost the ability to synthesize biologically active nikkomycin, indicating that sanF is essential for nikkomycin biosynthesis. Received: 17 April 2000 / Accepted: 23 May 2000     

sanN encoding a dehydrogenase is essential for Nikkomycin biosynthesis in Streptomyces ansochromogenes

Nikkomycins are a group of peptidyl nucleoside antibiotics with potent fungicidal, insecticidal, and acaricidal activities. sanN was cloned from the partial genomic library of Streptomyces ansochromogenes 7100. Gene disruption and complementation analysis demonstrated that sanN is essential for nikkomycin biosynthesis in S. ansochromogenes. Primer extension assay indicated that sanN is transcribed from two promoters (sanN-P1 and sanN-P2), and sanN-P2 plays a more important role in nikkomycin biosynthesis. Purified recombinant SanN acts as a dehydrogenase to convert benzoate-CoA to benzaldehyde in a random-order mechanism in vitro, with respective Kcat/Km values of 3.8 mM-1s-1 and 12.0 mM-1s-1 toward benzoate-CoA and NADH, suggesting that SanN catalyzes the formation of picolinaldehyde during biosynthesis of nikkomycin X and Z components in the wild-type stain. These data would facilitate us to understand the biosynthetic pathway of nikkomycins and to consider the combinatorial synthesis of novel antibiotic derivatives.     

Nikkomycin quantitation in fermentation process by high-performance liquid chromatography

Summary Nikkomycins are nucleoside-peptide antibiotics, produced by Streptomyces tendae. In contrast to any biological evaluation, high-performance liquid chromatography provided the quantitation of five nikkomycin components from the culture filtrate of the fermentation broth.     

Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo.

Nikkomycin Z inhibits chitin synthase in vitro but does not exhibit antifungal activity against many pathogens. Assays of chitin synthase isozymes and growth assays with isozyme mutants were used to demonstrate that nikkomycin Z is a selective inhibitor of chitin synthase 3. The resistance of chitin synthase 2 to nikkomycin Z in vitro is likely responsible for the poor activity of this antibiotic against Saccharomyces cerevisiae.     

Nikkomycin Z is an effective inhibitor of the chytrid fungus linked to global amphibian declines

Fungal infections in humans, wildlife, and plants are a growing concern because of their devastating effects on human and ecosystem health. In recent years, populations of many amphibian species have declined, and some have become extinct due to chytridiomycosis caused by the fungal pathogen Batrachochytrium dendrobatidis. For some endangered amphibian species, captive colonies are the best intermediate solution towards eventual reintroduction, and effective antifungal treatments are needed to cure chytridiomycosis and limit the spread of this pathogen in such survival assurance colonies. Currently, the best accepted treatment for infected amphibians is itraconazole, but its toxic side effects reduce its usefulness for many species. Safer antifungal treatments are needed for disease control. Here, we show that nikkomycin Z, a chitin synthase inhibitor, dramatically alters the cell wall stability of B. dendrobatidis cells and completely inhibits growth of B. dendrobatidis at 250 μM. Low doses of nikkomycin Z enhanced the effectiveness of natural antimicrobial skin peptide mixtures tested in vitro. These studies suggest that nikkomycin Z would be an effective treatment to significantly reduce the fungal burden in frogs infected by B. dendrobatidis.     

Tn4560在圈卷产色链霉菌中的转座及其在尼可霉素生物合成相关基因克隆中的应用

采用常规转化方法用来自天蓝色链霉菌J1 5 0 1的质粒pUC1 1 6 9(pMT6 6 0∷Tn45 5 6∷vph)多次转化尼可霉素产生菌圈卷产色链霉菌野生型 71 0 0的原生质体 ,均未得到转化子。采用限制性热衰减法于 5 0℃ ,3 0min溶菌制备 71 0 0的原生质体 ,获得了转化子 ,但转化频率极低 ,只有 0 4个转化子 μgDNA。用来自 71 0 0的pUC1 1 6 9再转化不含pUC1 1 6 9的 71 0 0原生质体 ,转化频率提高 1 0 3 ～ 1 0 4 倍。于 3 9℃ ,MM Vio条件下培养携带有pUC1 1 6 9的 71 0 0孢子 ,Tn45 6 0发生转座 ,筛选到 40 6 8个转座菌落 ,并从中得到 8株尼可霉素阻断突变株 ;对这 8株突变株的总DNA进行Southern杂交分析表明 ,Tn45 6 0至少在 4个不同的位点插入到 71 0 0的染色体上。用实验室已获得的与尼可霉素生物合成有关的 3 0kbDNA片段为探针和经不同酶切的 8株突变株的总DNA进行Southern杂交 ,结果表明 ,除阻断突变株Nik5有杂交信号且杂交信号大小均同野生型…     

Nikkomycin Z counteracts rylux BSU and Congo red inhibition ofSaccharomyces cerevisiae growth but does not prevent formation of aberrant cell walls

Rylux BSU and Congo red bind to chitin, interfere with proper cell-wall assembly, and stimulate chitin synthesis by increasing, most probably, chitin synthase 3 (ChS3) levels inSaccharomyces cerevisiae. On the other hand, the antibiotic nikkomycin Z inhibits chitin synthesis competitively. As ChS3 is the critical target of nikkomycin Z, its effect was tested in cells inhibited in growth by Rylux BSU or Congo red. Nikkomycin Z counteracted this inhibition but did not counteract aberrant cell-wall formation. These results indicate that chitin synthesis stimulation is the key step in Rylux BSU and Congo red inhibition and support the idea that increase in chitin synthesis represents a compensatory response to damaged cell-wall structure. As Rylux BSU and Congo red bind to newly synthesized chitin, further damage is caused in the wall and the response works in this case contrariwise. Nikkomycin Z breaks this vicious circle by counteracting the chitin synthesis stimulation.     

Cloning and Function of <Emphasis Type="Italic">sanQ</Emphasis>: A Gene Involved in Nikkomycin Biosynthesis of <Emphasis Type="Italic">Streptomyces ansochromogenes</Emphasis>

A 2.8-kb BamHI fragment was cloned from the cosmid library of Streptomyces ansochromogenes by using the 1.35-kb BamHI-ApaI fragment of sanO involved in nikkomycin biosynthesis as a probe. Sequence analysis showed that the BamHI fragment contains an open reading frame with 1191 bp, which was designated sanQ. In search of databases, the deduced product of sanQ gene has 56% similarity to the cytochrome P450. sanQ gene was inactivated by insertion of a kanamycin resistance gene. The resulting disruptants failed to produce nikkomycin X, but nikkomycin Z was at the same level as the wild type, indicating that sanQ is essential for the biosynthesis of nikkomycin X. Received: 26 November 2001 / Accepted: 21 December 2001     

Identification and Characterization of <Emphasis Type="Italic">sanH</Emphasis> and <Emphasis Type="Italic">sanI</Emphasis> Involved in the Hydroxylation of Pyridyl Residue During Nikkomycin Biosynthesis in <Emphasis Type="Italic">Streptomyces ansochromogenes</Emphasis>

Nikkomycins are highly potent inhibitors of chitin synthase. The nikkomycin biosynthetic gene cluster has been cloned from Streptomyces asochromogenes. Two cytochrome P450 monooxygenase genes (sanQ, sanH) and one ferredoxin gene (sanI) were found in the cluster. It was reported that SanQ is involved in the hydroxylation of l-His, a key step in 4-formyl-4-imidazolin-2-one base biosynthesis. Here, we have studied the function of sanH and sanI. Disruption of sanH abolished the production of nikkomycin X and Z, but it accumulated one dominant component nikkomycin Lx, which is the nikkomycin X analog lacking the hydroxy group at the pyridyl residue. The sanI disruption mutant accumulated predominantly nikkomycin Lx in addition to nikkomycin X and Z. The nikkomycin production profile of the sanH and sanI double disruption mutant was the same as that of the sanH disruption mutant. These results confirmed that SanH is essential for the hydroxylation of pyridyl residue in nikkomycin biosynthesis of S. ansochromogenes and first demonstrated that SanI is an effective electron donor for SanH, but not for SanQ in vivo.